STOCK TITAN
  1. Home
  2. Sec-filings
  3. KYMR
  4. [Form 4] Kymera Therapeutics, Inc. Insider Trading Activity

[Form 4] Kymera Therapeutics, Inc. Insider Trading Activity

Filing Impact
(Very High)
Filing Sentiment
(Very Negative)
Form Type
4

Rhea-AI Filing Summary

Kymera Therapeutics, Inc. director-affiliated funds reported sizable open-market sales of common stock. Venture funds associated with director Bruce Booth sold a combined 398,765 shares of Kymera common stock in 30 open-market transactions from June 23–25, 2026. The trades were executed through Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. under a pre-arranged Rule 10b5-1 trading plan adopted on December 11, 2025. Reported sale prices were weighted averages, with individual trades occurring in ranges from about $99.95 to $119.0789 per share. Booth is a member of the general partners of these funds and disclaims Section 16 beneficial ownership except for any pecuniary interest.

Positive

  • None.

Negative

  • None.
Insider Booth Bruce
Role null
Sold 398,765 shs ($43.99M)
Type Security Shares Price Value
Sale Common Stock 9,994 $107.30 $1.07M
Sale Common Stock 159 $108.02 $17K
Sale Common Stock 14,351 $108.83 $1.56M
Sale Common Stock 1,915 $110.30 $211K
Sale Common Stock 614 $110.79 $68K
Sale Common Stock 719 $111.89 $80K
Sale Common Stock 10,215 $113.70 $1.16M
Sale Common Stock 9,229 $114.65 $1.06M
Sale Common Stock 58,205 $115.57 $6.73M
Sale Common Stock 81,500 $116.53 $9.50M
Sale Common Stock 24,268 $117.50 $2.85M
Sale Common Stock 19,089 $118.60 $2.26M
Sale Common Stock 1,399 $107.30 $150K
Sale Common Stock 23 $108.02 $2K
Sale Common Stock 2,011 $108.83 $219K
Sale Common Stock 265 $110.30 $29K
Sale Common Stock 86 $110.79 $10K
Sale Common Stock 100 $111.89 $11K
Sale Common Stock 1,437 $113.70 $163K
Sale Common Stock 1,289 $114.65 $148K
Sale Common Stock 8,389 $115.57 $970K
Sale Common Stock 11,375 $116.53 $1.33M
Sale Common Stock 3,359 $117.50 $395K
Sale Common Stock 2,646 $118.60 $314K
Sale Common Stock 103,688 $100.42 $10.41M
Sale Common Stock 14,513 $100.42 $1.46M
Sale Common Stock 14,490 $101.14 $1.47M
Sale Common Stock 2,029 $101.14 $205K
Sale Common Stock 1,235 $99.98 $123K
Sale Common Stock 173 $99.98 $17K
Holdings After Transaction: Common Stock — 3,333,349 shares (Indirect, See footnote)
Footnotes (1)
  1. This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $99.95 to $100.1037 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold each separate price within the ranges set forth in footnotes (2) and (5) through (18). These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. The Reporting Person is a member of AVA X LLC and disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of his pecuniary interest therein, if any. The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF"). Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVOF. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF, except to the extent of his pecuniary interest therein, if any. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $99.95 to $100.9487 inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $100.95 to $101.5246 inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $106.40 to $107.3612 inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $107.4762 to $108.3781 inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.5492 to $109.4604 inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.66 to $110.57 inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.72 to $110.96 inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.82 to $111.96 inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $113.0556 to $114.0429 inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $114.0602 to $115.0549 inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $115.0739 to $116.0726 inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.0783 to $117.0773 inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $117.0787 to $118.0736 inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $118.0793 to 119.0789 inclusive.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Booth Bruce
(Last)(First)(Middle)
C/O KYMERA THERAPEUTICS, INC.
500 NORTH BEACON STREET, FLOOR 4
(Street)
WATERTOWN MASSACHUSETTS 02472
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Kymera Therapeutics, Inc. [ KYMR ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/23/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/23/2026S(1)1,235D$99.98(2)3,461,521ISee footnote(3)
Common Stock06/23/2026S(1)173D$99.98(2)613,589ISee footnote(4)
Common Stock06/24/2026S(1)103,688D$100.42(5)3,357,833ISee footnote(3)
Common Stock06/24/2026S(1)14,513D$100.42(5)599,076ISee footnote(4)
Common Stock06/24/2026S(1)14,490D$101.14(6)3,343,343ISee footnote(3)
Common Stock06/24/2026S(1)2,029D$101.14(6)597,047ISee footnote(4)
Common Stock06/25/2026S(1)9,994D$107.3(7)3,333,349ISee footnote(3)
Common Stock06/25/2026S(1)159D$108.02(8)3,333,190ISee footnote(3)
Common Stock06/25/2026S(1)14,351D$108.83(9)3,318,839ISee footnote(3)
Common Stock06/25/2026S(1)1,915D$110.3(10)3,316,924ISee footnote(3)
Common Stock06/25/2026S(1)614D$110.79(11)3,316,310ISee footnote(3)
Common Stock06/25/2026S(1)719D$111.89(12)3,315,591ISee footnote(3)
Common Stock06/25/2026S(1)10,215D$113.7(13)3,305,376ISee footnote(3)
Common Stock06/25/2026S(1)9,229D$114.65(14)3,296,147ISee footnote(3)
Common Stock06/25/2026S(1)58,205D$115.57(15)3,237,942ISee footnote(3)
Common Stock06/25/2026S(1)81,500D$116.53(16)3,156,442ISee footnote(3)
Common Stock06/25/2026S(1)24,268D$117.5(17)3,132,174ISee footnote(3)
Common Stock06/25/2026S(1)19,089D$118.6(18)3,113,085ISee footnote(3)
Common Stock06/25/2026S(1)1,399D$107.3(7)595,648ISee footnote(4)
Common Stock06/25/2026S(1)23D$108.02(8)595,625ISee footnote(4)
Common Stock06/25/2026S(1)2,011D$108.83(9)593,614ISee footnote(4)
Common Stock06/25/2026S(1)265D$110.3(10)593,349ISee footnote(4)
Common Stock06/25/2026S(1)86D$110.79(11)593,263ISee footnote(4)
Common Stock06/25/2026S(1)100D$111.89(12)593,163ISee footnote(4)
Common Stock06/25/2026S(1)1,437D$113.7(13)591,726ISee footnote(4)
Common Stock06/25/2026S(1)1,289D$114.65(14)590,437ISee footnote(4)
Common Stock06/25/2026S(1)8,389D$115.57(15)582,048ISee footnote(4)
Common Stock06/25/2026S(1)11,375D$116.53(16)570,673ISee footnote(4)
Common Stock06/25/2026S(1)3,359D$117.5(17)567,314ISee footnote(4)
Common Stock06/25/2026S(1)2,646D$118.6(18)564,668ISee footnote(4)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025.
2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $99.95 to $100.1037 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold each separate price within the ranges set forth in footnotes (2) and (5) through (18).
3. These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. The Reporting Person is a member of AVA X LLC and disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of his pecuniary interest therein, if any.
4. The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF"). Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVOF. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF, except to the extent of his pecuniary interest therein, if any.
5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $99.95 to $100.9487 inclusive.
6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $100.95 to $101.5246 inclusive.
7. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $106.40 to $107.3612 inclusive.
8. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $107.4762 to $108.3781 inclusive.
9. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.5492 to $109.4604 inclusive.
10. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.66 to $110.57 inclusive.
11. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.72 to $110.96 inclusive.
12. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.82 to $111.96 inclusive.
13. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $113.0556 to $114.0429 inclusive.
14. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $114.0602 to $115.0549 inclusive.
15. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $115.0739 to $116.0726 inclusive.
16. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.0783 to $117.0773 inclusive.
17. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $117.0787 to $118.0736 inclusive.
18. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $118.0793 to 119.0789 inclusive.
Remarks:
Due to the 30 line limitation in Table I, this report is being filed across two forms. This is the first of two filings.
/s/ Ommer Chohan, Attorney-in-Fact06/25/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR